文献速递肿瘤 PET/CT

[68Ga]Ga-RAYZ-8009(靶向磷脂酰肌醇蛋白聚糖3的肝细胞癌显像化合物)的生物分布与辐射剂量学

Biodistribution and Radiation Dosimetry of [68Ga]Ga-RAYZ-8009, a Glypican 3-Targeting Compound for Imaging of Hepatocellular Carcinoma.
PubMed 文献 · J Nucl Med · 2025-11-03

本研究纳入6例经组织学确诊或临床/影像学怀疑肝细胞癌的患者,静脉注射103–167 MBq(均值±标准差150±22 MBq)的[68Ga]Ga-RAYZ-8009后行全身PET/CT显像,计算器官吸收剂量与有效剂量。注射标准活度150 MBq时男性参考体模的中位有效剂量为3.6 mSv,肾脏吸收剂量最高,其次为胃壁和红骨髓。结论认为该示踪剂在肝细胞癌患者中具有良好的生物分布和剂量学特征。

要点

  • 6例肝细胞癌患者注射[68Ga]Ga-RAYZ-8009后行全身PET/CT,于注射后10分钟、1小时、2小时、4小时和7小时采集。
  • 注射150 MBq时男性参考体模中位有效剂量为3.6 mSv。
  • 肾脏吸收剂量最高,男性与女性参考体模中位值分别为0.175与0.179 mGy/MBq。

核心结论

  • [68Ga]Ga-RAYZ-8009在肝细胞癌患者中显示出良好的生物分布和剂量学特征。

研究设计与样本

  • 纳入6例经组织学确诊肝细胞癌或临床/影像学怀疑肝细胞癌的患者。
  • 静脉注射103–167 MBq(均值±标准差150±22 MBq)的[68Ga]Ga-RAYZ-8009。
  • 于注射后10分钟、1小时、2小时、4小时和7小时行全身PET/CT扫描。
  • 计算各器官时间-放射性活度曲线,采用IDAC-Dose 2.1计算平均器官吸收剂量与有效剂量。

主要发现

  • 注射标准活度150 MBq时,男性参考体模的中位有效剂量为3.6 mSv。
  • 肾脏吸收剂量最高,男性参考体模中位0.175 mGy/MBq vs 女性参考体模中位0.179 mGy/MBq。
  • 胃壁吸收剂量次之,男性参考体模中位0.060 mGy/MBq vs 女性参考体模中位0.062 mGy/MBq。
  • 红骨髓吸收剂量在男性和女性参考体模中中位均为0.044 mGy/MBq。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glypican 3 is highly expressed in hepatocellular carcinoma (HCC), rendering it a promising target for disease imaging. [68Ga]Ga-RAYZ-8009 is a recently introduced PET tracer selective for glypican 3. To further assess the safety and suitability of this radiopharmaceutical in a clinical setting, whole-body distribution and radiation dosimetry were evaluated. Methods: Six patients with histologically confirmed HCC or clinical or imaging-based suspicion of HCC were intravenously injected with 103-167 MBq of [68Ga]Ga-RAYZ-8009 (mean ± SD, 150 ± 22 MBq). Whole-body PET/CT scans were acquired at 10 min, 1 h, 2 h, 4 h, and 7 h after tracer injection. Time-activity curves per organ were determined, and mean organ-absorbed doses and effective doses were calculated using IDAC-Dose 2.1. Results: Injection of a standard activity of 150 MBq of [68Ga]Ga-RAYZ-8009 resulted in a median effective dose of 3.6 mSv for the male reference phantom. The highest absorbed organ doses were observed in the kidneys (median of 0.175 mGy/MBq and 0.179 mGy/MBq for male and female reference phantom, respectively), followed by the red bone marrow (median of 0.044 mGy/MBq for male/female reference phantom) and the stomach wall (median of 0.060 and 0.062 mGy/MBq for male and female reference phantom, respectively). Conclusion: [68Ga]Ga-RAYZ-8009 demonstrates a favorable biodistribution and dosimetry in patients with HCC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Viering O, Brosch-Lenz J, Bundschuh RA, et al. Biodistribution and Radiation Dosimetry of [68Ga]Ga-RAYZ-8009, a Glypican 3-Targeting Compound for Imaging of Hepatocellular Carcinoma. J Nucl Med. 2025. PMID: 40998729. doi:10.2967/jnumed.125.270267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。